I am chief of the Division of Neurosurgery at The Children’s Hospital of Philadelphia and an attending neurosurgeon specializing in pediatric brain tumors. I operate on every type of brain tumor, but I have a particular interest in low-grade gliomas, medulloblastomas and atypical teratoid rhabdoid tumors (AT/RT) as well as skull-base tumors such as acoustic neuromas, craniopharyngiomas, and large ependymomas in cerebellopontine angle. With my otolaryngologist colleagues I am also developing an endonasal skull base program at CHOP.
It is my privilege to partner with The Children’s Hospital of Philadelphia Research Institute, which is at the forefront of pediatric genetic research. Here we are working to develop new treatments that one day will help thousands of children with brain tumors. Currently, tissue from every brain tumor we treat is sent to the laboratory for sequencing to detect genetic abnormalities. Tumors that look identical under the microscope may in fact have significant genetic variations, explaining why one tumor may respond well to chemotherapy and radiation, and another may not. Our goal is to personalize the post-operative chemotherapy and radiation regimen by specifically targeting the treatment based on the genetic abnormality.
At CHOP we are also conducting research into the cell signaling mechanisms of brain tumors and are supported by several competitive grants including the NIH. Once we have identified an abnormality in the DNA code, the challenge is to then figure out how that abnormality translates into a functional abnormality. Once we understand that we have a new potential tumor target.
An example: we have recently found that the B-Raf gene is altered in many low- and high-grade gliomas in children. B-Raf is the same gene that is often abnormal in melanoma. Now we are collaborating with pharmaceutical companies who have already developed promising melanoma drugs and we have begun applying these medicines to our brain tumor specimens. If it turns out that a brain tumor with a B-Raf mutation behaves in the same way as melanoma, we could have an effective new treatment in the next few years.
There are countless reasons patients come to CHOP first for the best care. It is important for brain tumor patients to have their surgery at CHOP because we are currently unable to enroll tumors resected elsewhere into our genetic sequencing protocol. Without the genetic information not all the benefits of our groundbreaking research and experience would be available to the patient.
Ultimately, surgery is not the answer. We can take the tumor out but the biology of most of these tumors is such that they will come back. A cure for brain tumors lies in better understanding of their biology so we can develop more effective post-operative treatments to prevent them from recurring.
The collaborative spirit at CHOP is remarkable. Working with the basic science and tumor research teams, with access to the most advanced technology, we are now on an exciting precipice, poised for exponential growth in the near future. Hopefully in the next decade or two the new discoveries and therapies will put me out of the tumor business - which is really the ultimate goal.
- Education and Training
MD - Johns Hopkins University School of Medicine, Baltimore, MD
General Surgery - Johns Hopkins Hospital, Baltimore, MD
Neurosurgery - Johns Hopkins Hospital, Baltimore, MD
Neuro-Oncology Research Fellow - Johns Hopkins Hospital, Baltimore, MDPediatric Neurosurgery - The Children's Hospital of Philadelphia, Philadelphia, PA
- Titles and Academic Titles
Chief, Division of Neurosurgery
Associate Professor of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania
- Departments and Services
Beslow LA, Ichord RN, Kasner SE, Mullen MT, Licht DJ, Smith SE, Storm PB, Jordan LC, Messé SR. ABC/XYZ estimates intracerebral hemorrhage volume as a percent of total brain volume in children. Stroke. 2010 Apr;41(4):691-4. Epub 2010 Feb 24. Cited in PubMed: PMID 20181678. Read abstract
Marsh ED, Peltzer B, Brown MW 3rd, Wusthoff C, Storm PB Jr, Litt B, Porter BE. Interictal EEG spikes identify the region of electrographic seizure onset in some, but not all, pediatric epilepsy patients. Epilepsia. 2010 Apr;51(4):592-601. Epub 2009 Sep 22. Cited in PubMed: PMID 19780794. Read abstract
Heuer GG, Hardesty DA, Bhowmick D, Bailey R, Magge SN, Storm, PB. Treatment of pediatric atlantoaxial instability with harms fusion constructs. Eur Spine. Epub 2009 Apr 9. Cited in PubMed: PMID 19357876. Read abstract
Posters and Presentations
May 2009, Grand Rounds Department of Neurosurgery, Abington Hospital, Abington, PA. Pediatric spine surgery and the FOP story.
- Editorial and Academic Positions
2009, Faculty, AO Spine North America, Principles and Treatment of Spinal Disorders for Residents and Fellows, Las Vegas, NV
2009, Brain and Behavior Course for first year medical students at the University of Pennsylvania, Philadelphia, PA
2009, Faculty, AO Spine North America, Principles and Treatment of Spinal Disorders for Residents and Fellows, Philadelphia, PA
2009, Faculty, Pediatric Spinal Deformity Residents Course, Philadelphia, PA
- Editorial and Academic Positions